Loading...
After decades of limited therapeutic progress in metastatic urothelial cancer, a number of novel therapies have been granted FDA approval in the last several years. Although still in rapid evolution, the current standard of care is platinum-based chemotherapy followed by checkpoint inhibitors (anti-PD-1/PD-L1) either as maintenance therapy or upon disease progression.
Enfortumab vedotin (EV), a monoclonal antibody–drug conjugate directed against nectin-4, was initially granted FDA approval based on compelling phase 2 trial data. Investigators now report the results of an international phase 3 trial in which patients with disease progression following platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor were randomized to receive EV or c…